<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168519</url>
  </required_header>
  <id_info>
    <org_study_id>51/02</org_study_id>
    <nct_id>NCT00168519</nct_id>
  </id_info>
  <brief_title>Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes</brief_title>
  <official_title>Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baker Heart Research Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine whether glucose metabolism can be improved by&#xD;
      administering a substance (nitric oxide donor) normally released by muscles during exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To determine whether acute infusion of sodium nitroprusside, an NO donor, increases&#xD;
      leg glucose uptake at rest in patients with type 2 diabetes.&#xD;
&#xD;
      Twenty male type 2 diabetic patients aged between 30 and 60 years will be recruited from our&#xD;
      clinic and through advertisement. The inclusion criteria:&#xD;
&#xD;
        -  non-smokers&#xD;
&#xD;
        -  free of overt coronary disease (stress ECG)&#xD;
&#xD;
        -  body mass index &lt; 35 kg.m-2&#xD;
&#xD;
        -  fasting plasma glucose &gt; 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose&#xD;
           levels of &gt; 11.1 mmol.L-1&#xD;
&#xD;
        -  unmedicated (diet controlled)&#xD;
&#xD;
      The leg blood flow (thermodilution) and glucose uptake responses (arterial-venous&#xD;
      differences) to three cumulative doses of sodium nitroprusside (0.1, 0.3 and 0.6&#xD;
      ug.kg-1.min-1, 10 mins per dose) infused into the femoral artery using techniques established&#xD;
      in our laboratory will be assessed. Doses are based on our extensive unpublished observations&#xD;
      and have been calculated to lie on the linear part of the dose-response curve and to induce&#xD;
      local and not systemic hemodynamic effects. As a control we will also assess responses to the&#xD;
      nitrate independent vasodilator, Verapamil (Isoptin) (1, 3 and 6 ug.kg-1.min-1 Doses).&#xD;
      Verapamil is a calcium channel antagonist which causes vasodilatation by direct actions on&#xD;
      the smooth muscle. Doses will be titrated to give similar blood flow responses and the two&#xD;
      drugs will be administered in randomized order with a 60 min wash-out period. Verapamil doses&#xD;
      will be determined in pilot experiments. Vastus lateralis biopsies will be performed at&#xD;
      baseline and after the highest dose of each drug and cGMP and GLUT-4 translocation measured.&#xD;
&#xD;
      A single Vastus lateralis biopsy will be performed as a comparison against type 2 diabetics.&#xD;
&#xD;
      Significance: This study will determine whether acute NO supplementation stimulates muscle&#xD;
      GLUT-4 translocation and glucose uptake in patients with type 2 diabetes.&#xD;
&#xD;
      Pilot Study: To determine whether oral nitrates increase exhaled NO levels in healthy&#xD;
      volunteers &amp; to compare isosorbide mononitrate (ISMN) with pentaerythritol tetranitrate&#xD;
      (PETN) to determine which drug is more effective in increasing exhaled NO.&#xD;
&#xD;
      Fifteen healthy male volunteers (as determined via a medical screening) aged between 18 and&#xD;
      65 years will be recruited through advertisement. The inclusion criteria for healthy controls&#xD;
      will be:&#xD;
&#xD;
        -  non-smokers&#xD;
&#xD;
        -  free of overt coronary disease (ECG)&#xD;
&#xD;
        -  body mass index &lt; 30 kg.m-2&#xD;
&#xD;
        -  fasting plasma glucose &lt; 6.1 mmol.L-1&#xD;
&#xD;
        -  unmedicated&#xD;
&#xD;
      Blood samples will be obtained and an oral glucose tolerance test (OGTT) performed. Baseline&#xD;
      exhaled nitric oxide (NO) and pulmonary blood flow will be measured in collaboration with Dr&#xD;
      Bruce Thompson from the Alfred Respiratory Department. Sodium nitroprusside (SNP) is a known&#xD;
      NO donor and will be used as a positive control. Following baseline measurements participants&#xD;
      will receive an intravenous (forearm vein) infusion of SNP (titrated from 0.3ug/kg/min to a&#xD;
      maximum of 3 ug/kg/min over 30 minutes). Blood pressure will be monitored throughout using an&#xD;
      automated sphygmomanometer. Post infusion exhaled NO and pulmonary blood flow will be&#xD;
      measured.&#xD;
&#xD;
      Participants will then commence the second phase of the study to determine whether ISMN and&#xD;
      PETN increase exhaled NO levels and to determine which drug is more potent in this regard.&#xD;
&#xD;
      Visit 2, 3 &amp; 4: Participants will receive each of the following study medications in a&#xD;
      randomised Latin square design:&#xD;
&#xD;
        -  Placebo administered once on the morning of Visit 2, 3 or 4,&#xD;
&#xD;
        -  extended release ISMN mononitrate (120mg ) administered once on the morning of Visit 2,&#xD;
           3 or 4; &amp;&#xD;
&#xD;
        -  pentaerythritol tetranitrate (160mg administered once on the morning of Visit 2, 3 or&#xD;
           4).&#xD;
&#xD;
      There will be a 7-day wash-out period between each treatment/visit. Participants will undergo&#xD;
      repeated measures of exhaled NO, pulmonary blood flow and OGTT three hours after each study&#xD;
      drug has been administered. Blood will be taken prior to and every hour after the participant&#xD;
      has taken each drug for measurement of NO metabolites (e.g. nitrite/nitrate, nitrosothiols,&#xD;
      nitrosohemoglobin). Nitrate drugs are occasionally associated with headache and dizziness.&#xD;
      Headaches can be treated with paracetamol.&#xD;
&#xD;
      Endpoints at baseline and post treatments will be:&#xD;
&#xD;
        -  Post 75g oral glucose load&#xD;
&#xD;
        -  Exhaled NO levels&#xD;
&#xD;
        -  Pulmonary blood flow&#xD;
&#xD;
      Significance: Once the most effective NO donor has been determined it will be utilized in the&#xD;
      chronic nitrate study described in Aim 2.&#xD;
&#xD;
      Aim 2: To determine whether chronic nitrate therapy for 12 weeks improves glucose tolerance&#xD;
      and HbA1c in patients with type 2 diabetes.&#xD;
&#xD;
      Twenty male type 2 diabetic subjects aged between 30 and 60 years and meeting the inclusion&#xD;
      criteria specified in Aim 1 will be recruited from our clinics and through advertisement.&#xD;
      Patients will be randomized to 12 weeks of treatment with both long-acting nitrate therapy&#xD;
      (isosorbide mononitrate 60mg daily, Imdur) and placebo (cross-over design). Primary endpoints&#xD;
      will be:&#xD;
&#xD;
        -  glycated haemoglobin (HbA1c)&#xD;
&#xD;
        -  whole body glucose uptake at rest (stable glucose tracer methodology, (39-41))&#xD;
&#xD;
        -  whole body glucose uptake after (0-2 hrs) a 75 gm oral glucose load (tracer methodology)&#xD;
&#xD;
        -  skeletal muscle cGMP and GLUT-4 translocation (vastus lateralis muscle biopsy before and&#xD;
           after glucose load)&#xD;
&#xD;
        -  skeletal muscle glycogen, lactate, phosphocreatine, creatine and ATP Significance: This&#xD;
           study will determine whether chronic nitrate therapy increases GLUT-4 translocation /&#xD;
           glucose uptake and has beneficial effects on glycaemic control in patients with type 2&#xD;
           diabetes.&#xD;
&#xD;
      Aim 3:&#xD;
&#xD;
      To determine whether acute infusion of AICAR, an AMP analogue, increases leg glucose uptake&#xD;
      at rest in patients with type 2 diabetes.&#xD;
&#xD;
      Twenty healthy males and twenty male type 2 diabetics aged between 30 and 60 years will be&#xD;
      recruited from our clinic and through advertisement. The inclusion criteria for the diabetics&#xD;
      will be:&#xD;
&#xD;
        -  non-smokers&#xD;
&#xD;
        -  free of overt coronary disease (stress ECG)&#xD;
&#xD;
        -  body mass index &lt; 35 kg.m-2&#xD;
&#xD;
        -  fasting plasma glucose &gt; 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose&#xD;
           levels of &gt; 11.1 mmol.L-1&#xD;
&#xD;
        -  unmedicated (diet controlled)&#xD;
&#xD;
      The leg blood flow (thermodilution) and glucose uptake (arterial-venous differences) response&#xD;
      to a 60 minute intra-femoral infusion of AICAR (1 mg.kg-1.min-1, Clinalfa, Switzerland) using&#xD;
      techniques established in our laboratory will be assessed. As a control we will also measure&#xD;
      responses to vehicle (saline) infusion prior to commencing the dose response curve (60 min).&#xD;
      Plasma free fatty acids, glycerol, triglycerides and lactate will be determined and blood&#xD;
      gases will be measured to assess respiratory quotient. Vastus lateralis biopsies will be&#xD;
      performed at baseline and after AICAR and the following parameters quantitated:&#xD;
&#xD;
        -  AMPK activity&#xD;
&#xD;
        -  nNOS phosphorylation&#xD;
&#xD;
        -  NOS activity&#xD;
&#xD;
        -  GLUT-4 translocation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucose metabolism</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitroprusside, pentalong, imdur, AICAR, isoptin</intervention_name>
    <description>Sodium Nitroprusside - one 30 minute intravenous infusion&#xD;
Pentalong - two tablets orally (total 160mg)&#xD;
Imdur - two tablets orally (total 120mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with type 2 diabetes&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Free of overt coronary disease (stress ECG)&#xD;
&#xD;
          -  Body mass index &lt; 35 kg.m-2&#xD;
&#xD;
          -  Fasting plasma glucose &gt; 7 mmol.L-1 and / or post 75 gm oral glucose load plasma&#xD;
             glucose levels of &gt; 11.1 mmol.L-1&#xD;
&#xD;
          -  Unmedicated (diet controlled)&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Free of overt coronary disease (ECG)&#xD;
&#xD;
          -  Body mass index &lt; 30 kg.m-2&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 6.1 mmol.L-1&#xD;
&#xD;
          -  Unmedicated&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bronwyn A Kingwell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker Heart Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baker Heart Research Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Blood Glucose</keyword>
  <keyword>Exercise</keyword>
  <keyword>Muscle Contraction</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Nitrates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

